Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05933265 · ClinicalTrials.gov registry record · Phase 1

Study of LP-184 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor and NSCLC, sponsored by Lantern Pharma.

Recruiting
Registry status
Phase 1
Development phase
175
Enrollment target
9
Study locations

NCT05933265 is a Phase 1 study of Advanced Solid Tumor and NSCLC that is actively recruiting participants, run by Lantern Pharma. The registered enrollment target is 175 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 9 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05933265, a Phase 1 study of Advanced Solid Tumor and NSCLC, is actively recruiting participants, sponsored by Lantern Pharma.

RECRUITING
Registry status
Phase 1
Development phase
175 participants
Enrollment target
9
Study locations

Study Summary

The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Participants will receive LP-184 infusion during Day 1 and Day 8 of each 21-day cycle, for a minimum of two cycles. Patients will be monitored for safety, PK, and clinical activity

Conditions Studied

Advanced Solid Tumor NSCLC Pancreatic Adenocarcinoma Metastatic Solid Tumor GBM TNBC - Triple-Negative Breast Cancer DDR Gene Mutation

Interventions

  • DRUG Olaparib
  • DRUG Spironolactone
  • DRUG LP-184

Study Locations (9)

Arkansas

  • Highlands Oncology Group - Springdale

California

  • Cancer and Blood Specialty Clinic - Los Alamitos

Illinois

  • Northwest Oncology & Hematology - Rolling Meadows

Indiana

  • Indiana University Melvin and Bren Simon Cancer Center - Indianapolis

Kentucky

  • Norton Healthcare, Inc. - Louisville

Maryland

  • John Hopkins - The Sidney Kimmel Comprehensive Cancer Center - Baltimore

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • UT Health Science Center San Antonio - San Antonio

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2023-06-09
Est. Completion 2025-09-09
Phase Phase 1

Sponsor

Lantern Pharma

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05933265

The ClinicalTrials.gov registry entry for NCT05933265 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The listed sponsor is Lantern Pharma, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which Olaparib is the first listed.

NCT05933265 reports 9 study locations spanning 9 distinct geographic areas - top geographies include Arkansas, California, Illinois.

Frequently Asked Questions

What is clinical trial NCT05933265 about?

NCT05933265 is a clinical study titled "Study of LP-184 in Patients With Advanced Solid Tumors". The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of...

What is the current status of trial NCT05933265?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 175 participants. The study started on 2023-06-09. Estimated completion is 2025-09-09.

What conditions does trial NCT05933265 study?

This clinical trial studies the following conditions: Advanced Solid Tumor, NSCLC, Pancreatic Adenocarcinoma, Metastatic Solid Tumor, GBM.

What interventions are being tested in trial NCT05933265?

The interventions under investigation include: Olaparib (DRUG), Spironolactone (DRUG), LP-184 (DRUG).

Who is sponsoring clinical trial NCT05933265?

This trial is sponsored by Lantern Pharma, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05933265 being conducted?

This trial has 9 study locations across Arkansas, California, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

NSCLC

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.